Bronchoalveolar lavage fluid of lung cancer patients: Mapping the uncharted waters using proteomics technology

Oumeraci, Tonio; Schmidt, Bernd; Wolf, Thomas; Zapatka, Marc; Pich, Andreas; Brors, Benedikt; Eils, Roland; Fleischhacker, Michael; Schlegelberger, Brigitte; Neuhoff, Nils von

doi:10.1016/j.lungcan.2011.01.015

Cited by 15 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bronchoalveolar lavage (BAL) represents an alternative source of more specific lung cancer biomarkers due to its vicinity to tumor cells, its less complex protein composition, and the fact that it can be obtained through minimally invasive methods, compared with biopsies. 8 A number of potential biomarkers have already been found in bronchial fluids from lung cancer patients, 5 but few have proved to be useful in the clinic, because of their low sensitivity, specificity, and reproducibility. 9,10 Thus, identification and validation of diagnostic biomarkers for early detection and subtype classification of lung cancer patients is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

“…Proteomics, a powerful tool for global evaluation of protein expression, has been widely applied in cancer research, allowing the efficient identification of accurate and reproducible differentially expressed proteins in complex biological samples. 9 Several proteomic studies have used BAL samples to assess differential protein profiles in a number of lung-related diseases such as asthma, sarcoidosis, and cystic fibrosis, 11 but the suitability of BAL as a source of NSCLC biomarkers, was not reported until 2011 by Oumeraci et al, 8 based on a preliminary proof of concept using six lung cancer samples. Very recently, Pastor et al 12 have published the first proteomic study of NSCLC in BAL using two-dimensional polyacrilamide gel electrophoresis (2D-PAGE).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis

Uribarri¹,

Hormaeche²,

Zalacaín

et al. 2014

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis

Uribarri¹,

Hormaeche²,

Zalacaín

et al. 2014

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…The proof of principle for using BAL proteome analysis for lung cancer diagnosis was reported by Oumeraci et al . in which six BAL samples from non small cell lung cancer (NSCLC) patients were analyzed using a MALDI-TOF mass spectrometry based method 22 . Following, Pastor et al .…”

mentioning

confidence: 99%

Bronchoalveolar Lavage Proteomics in Patients with Suspected Lung Cancer

Carvalho

Cuco

Lavareda

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Lung cancer configures as one of the deadliest types of cancer. The future implementation of early screening methods such as exhaled breath condensate analysis and low dose computed tomography (CT) as an alternative to current chest imaging based screening will lead to an increased burden on bronchoscopy units. New approaches for improvement of diagnosis in bronchoscopy units, regarding patient management, are likely to have clinical impact in the future. Diagnostic approaches to address mortality of lung cancer include improved early detection and stratification of the cancers according to its prognosis and further response to drug treatment. In this study, we performed a detailed mass spectrometry based proteome analysis of acellular bronchoalveolar lavage (BAL) fluid samples on an observational prospective cohort consisting of 90 suspected lung cancer cases which were followed during two years. The thirteen new lung cancer cases diagnosed during the follow up time period clustered, based on liquid chromatography-mass spectrometry (LC-MS) data, with lung cancer cases at the time of BAL collection. Hundred and thirty-tree potential biomarkers were identified showing significantly differential expression when comparing lung cancer versus non-lung cancer. The regulated biomarkers showed a large overlap with biomarkers detected in tissue samples.

show abstract

“…Byproducts from the exible bronchoscopy procedure, such as bronchial washing uid (BWF) and/or bronchoalveolar lavage uid (BALF), may be a useful alternative to biopsy specimens. Bronchoscopy is routinely performed in patients with suspected lung cancer, and BALF is a speci c material that can re ect characteristics of the lung compartment [11]. Carvalho et al [12] performed mass spectrometry of BALF from 90 patients with suspected lung cancer and found signi cantly different biomarkers between the lung cancer and non-lung cancer groups.…”

Section: Introductionmentioning

confidence: 99%

Compared to plasma, bronchial washing fluid shows higher diagnostic yields for detecting EGFR-TKI sensitizing mutations by ddPCR in lung cancer

Lee

Kim

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The rate of diagnosis of advanced lung adenocarcinoma must be improved. In this study, we compared the detection rates of EGFR-tyrosine kinase inhibitor-sensitizing mutations (mEGFRs) in bronchial washing fluid (BWF) and the plasma of patients with lung adenocarcinoma using the tissue genotype as the standard reference.Methods: Paired blood and BWF specimens were collected from 73 patients with lung cancer. The tumor EGFR mutation status was determined by genotyping of the plasma and BWF samples using droplet digital PCR (ddPCR).Results: The study cohort included 26, 10, 10, and 27 patients with stage I, II, III, and IV disease. Of the 73 cases, 35 had a wild-type EGFR, and 19 had the L858R substitution and exon 19 deletion mutations. The areas under the receiver operator characteristic curves for sensitivity vs. specificity of ddPCR were 0.895 [95% confidence interval (CI): 0.822–0.969] for BWF and 0.686 (95% CI: 0.592–0.780) for plasma (p < 0.001). The fractional abundance was higher in BWF of the mEGFR-positive cases than in the plasma (p = 0.004), facilitating easy threshold setting and discrimination between mEGFR-positive and negative cases. When genotyping results obtained using plasma and BWF were compared for early lung cancer (stages I–IIIA), the diagnostic yields were significantly higher for BWF ddPCR, and the same tendency was observed for the advanced stages, suggesting that the BWF data may reflect the genotype status in early-stage patients.Conclusions: The mEGFR genotyping results obtained using BWF showed a higher diagnostic efficacy than did those obtained using the plasma. Thus, BWF-based genotyping may be a useful substitute for that using plasma in lung cancer.

show abstract

Bronchoalveolar lavage fluid of lung cancer patients: Mapping the uncharted waters using proteomics technology

Cited by 15 publications

References 9 publications

A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis

A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis

Bronchoalveolar Lavage Proteomics in Patients with Suspected Lung Cancer

Compared to plasma, bronchial washing fluid shows higher diagnostic yields for detecting EGFR-TKI sensitizing mutations by ddPCR in lung cancer

Contact Info

Product

Resources

About